KaydedilenlerDerginizi ekleyin

Dergiler / Bakırköy Tıp Dergisi / 2020 / Cilt: 16 - Sayı: 2

Natural Course of Branch Retinal Vein Occlusion up to 3 Months for Early Referral Cases

Erken Başvuran Retina Ven Dal Tıkanıklığı Olgularının İlk 3 Aylık Doğal Seyri

Emir Volkan ALTAN
İsmail Umut ONUR
Ozge Pinar AKARSU ACAR
Ulviye YİĞİT
Sayfa
114–119
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Our results indicate that delaying treatment up to 3 months is not associated with increased CMT or deteriorated BCVA for recent onset early referral BRVO cases.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: To evaluate functional and anatomical changes in branch retinal vein occlusion (BRVO) up to 3 months in early referral BCVA cases.
📊
Temel Bulgular & Veri:Method: Twenty-three eyes of 23 consecutive BRVO patients diagnosed within 4 weeks of symptom onset were enrolled in this prospective, observational study.
💡
Sonuç & Katkı:Our results indicate that delaying treatment up to 3 months is not associated with increased CMT or deteriorated BCVA for recent onset early referral BRVO cases.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: To evaluate functional and anatomical changes in branch retinal vein occlusion (BRVO) up to 3 months in early referral BCVA cases. Method: Twenty-three eyes of 23 consecutive BRVO patients diagnosed within 4 weeks of symptom onset were enrolled in this prospective, observational study. Eyes were followed up without treatment. Measurements in best corrected visual acuity (BCVA) and central macular thickness (CMT) at the baseline, 2 weeks, 1 month and 3 months were evaluated. Results: The improvement in mean BCVA from the baseline to 2 weeks (p=0.043), 1 month (p=0.012) and 3 months was found statistically significant (p=0.001). Despite a decrease in central macular thickness (CMT) was observed, the change in CMT from the baseline to 3 months did not reach a clinical significance (p=0.068). Conclusion: Considering the natural course in BRVO, follow-up without treatment may also be acceptable up to the first 3 months. Our results indicate that delaying treatment up to 3 months is not associated with increased CMT or deteriorated BCVA for recent onset early referral BRVO cases.

Abstract

Amaç: Erken başvuran retina ven dal tıkanıklığı (RVDT) olgularında ilk 3 aydaki işlevsel ve anatomik değişiklikleri incelemek. Yöntem: Semptomların ortaya çıkışıyla ilk 4 hafta içerisinde RVDT tanısı alan ardışık 23 hastanın 23 gözü prospektif, gözlemsel çalışmaya dahil edildi. Gözler sadece tedavisiz takip edildi. Başlangıçta alınan en iyi düzeltilmiş görme keskinliği (EİDGK) ve santral makula kalınlığı (SMK) ölçümleri 2. haftada, 1. ayda ve 3. ayda tekrarlandı. Bu parametrelerdeki değişimler analiz edildi. Bulgular: Ortalama EİDGK’de başlangıca göre 2. haftada, 1. ayda, 3. ayda istatistiksel olarak anlamlı düzelme kaydedildi (sırasıyla p=0,043, p=0,012, p=0,001). Ortalama SMK’da ise başlangıca göre 3. ayda azalma izlenmiş olsa da fark istatistiksel olarak anlamlı bulunmadı (p=0.068). Sonuç: RVDT’nin doğal seyri ile birlikte düşünüldüğünde ilk 3 aya kadar tedavisiz gözlem, bir seçenek olarak değerlendirilebilir. Çalışmamızın sonuçları, erken başvuran olgularda tedavinin 3 aya kadar bekletilmesinin EİDGK ve SMK parametreleri üzerinde olumsuz bir etki ilişkili olduğunu göstermemiştir.

🔖

Bu Makaleye Atıf Yap

ALTAN, E. V., ONUR, İ. U., ACAR, O. P. A., YİĞİT, U. (2020). Natural Course of Branch Retinal Vein Occlusion up to 3 Months for Early Referral Cases. Bakırköy Tıp Dergisi, Cilt: 16 - Sayı: 2, 114–119. https://ajindex.com/articles/131826

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Frangieh GT, Green WR, Barraquer-Somers E, et al. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol. 1982;100(7):1132-40. https://doi.org/10.1001/archopht.1982.01030040110020
  2. Bandello F, Querques G. Medical Retina. 2012
  3. ESASO Course Series. Basel, Karger. Vol 1. p. 111-8. https://doi.org/10.1159/isbn.978-3-8055-9991-7
  4. Coscas G, Loewenstein A, Augustin A, et al. Management of Retinal Vein Occlusion - Consensus Document. Ophthalmologica. 2011;226(1):4-28. https://doi.org/10.1159/000327391
  5. Laouri M, Chen E, Looman M, et al. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-8. doi: 10.1038/eye.2011.92. https://doi.org/10.1038/eye.2011.92
  6. Ip M, Hendrick A. Retinal Vein Occlusion Review. Asia-Pac J Ophthalmol. 2018;7:40-5. https://doi.org/10.22608/APO.2017442
  7. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094-1101.e5. https://doi.org/10.1016/j.ophtha.2010.01.058 Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271-82. https://doi.org/10.1016/0002-9394(84)90316-7 BVOS Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol. 1986;104(1):3441. https://doi.org/10.1001/archopht.1986.01050130044017
  8. Scott IU, VanVeldhuisen PC, Oden NL, et al. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Study Report 1: Baseline Associations between Central Retinal Thickness and Visual Acuity in Patients with Retinal Vein Occlusion. Ophthalmology. 2009;116(3):504-12. https://doi.org/10.1016/j.ophtha.2008.10.017 10. Campochiaro PA, Jeffrey S, Heier JS, et al. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112.e1. https://doi.org/10.1016/j.ophtha.2010.02.021 11. Haller J, Bandello F, Belfort R Jr, et al. OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):11341146.e3. https://doi.org/10.1016/j.ophtha.2010.03.032 12. Shroff D, Mehta DK, Arora R, et al. Natural history of macular s